List of GLP-1 Drugs: FDA Status by Brand (2026)

The Current List of GLP-1 Drugs (Table)

A "GLP-1 drug" here means a medicine whose FDA label calls it a GLP-1 receptor agonist, plus tirzepatide, whose label calls it a GIP and GLP-1 receptor agonist. The table covers every brand that meets the three conditions in the last note under the table. Brands that are withdrawn or unclear, including two that Drugs@FDA still lists as prescription (Adlyxin and a 2009 Byetta application), get their own table further down.

How we built this table:

• A brand is a name on a current manufacturer label (DailyMed) or a product in Drugs@FDA. Generics are not counted as separate drugs. Compounded drugs, products approved only outside the US and investigational drugs are left out.
• The approval date is the original approval of the brand's own FDA application. Labeling supplements are not new approvals, so Ozempic tablets share the 2019 Rybelsus application.
• Every row is active: for the same FDA application, Drugs@FDA lists a prescription product, a manufacturer label is on DailyMed, and FDA has not withdrawn the application's approval in the Federal Register. That means FDA lists it, not that your pharmacy has it in stock.

Reading the table: type, form and use

Most products are peptides given by injection. The exceptions are the semaglutide tablets and Foundayo, whose ingredient, orforglipron, is a small-molecule, nonpeptide GLP-1 receptor agonist. Trulicity is a fusion protein that joins a GLP-1 analog to part of a modified human IgG4 antibody. "Heart-event risk" is shorthand for each label's indication to reduce major adverse cardiovascular events (MACE), and each label sets its own population. Prices change too often for a table, so they live in our TrumpRx pricing guide.

Brand approval dates from Drugs@FDA, checked October 29, 2026. Hollow dots mark brands whose approval FDA has withdrawn, that are discontinued, or whose status is unclear in FDA records.

Same Drug, Different Names: GLP-1 Brands That Share a Molecule

The table holds 13 brand names if Ozempic tablets and Rybelsus count separately. They come from five GLP-1 ingredients, plus lixisenatide inside Soliqua.

• Semaglutide: Ozempic, Ozempic tablets, Rybelsus, Wegovy and Wegovy tablets. See what semaglutide is.
• Tirzepatide: Mounjaro and Zepbound, tirzepatide's two brand names.
• Liraglutide: Victoza, Saxenda, Xultophy (with insulin) and 11 approved generic applications.
• Dulaglutide: Trulicity only.
• Orforglipron: Foundayo only.

One molecule ends up with several names because each brand is its own FDA application with its own indications and doses. Ozempic and Wegovy, for example, are NDA 209637 and NDA 215256. The comparisons Ozempic vs Wegovy and Mounjaro vs Zepbound go brand by brand.

One trap if you check dates yourself: the "Initial U.S. Approval" line on a label gives the ingredient's first approval, not the brand's. The Wegovy label prints 2017, the Ozempic year. Wegovy itself was approved June 4, 2021.

Brand names grouped by active ingredient, per FDA labels, as of October 29, 2026.

A physician on four of these brands

Endocrinologist Susan Brian MD compares semaglutide (Ozempic, Wegovy) with tirzepatide (Mounjaro, Zepbound), including head-to-head trial results and her own prescribing views. It does not cover the full list above, and this page does not rank these drugs.

GLP-1 Drugs by FDA-Labeled Use

Which GLP-1 drugs are approved for weight loss?

Wegovy (injection and tablets), Zepbound, Saxenda and Foundayo, plus generic liraglutide labeled for weight management (Teva, Biocon and Orbicular hold generic applications whose labels carry Saxenda's weight indication). The Wegovy injection and Saxenda also cover some adolescents; Wegovy tablets, Zepbound and Foundayo are labeled for adults.

Which are approved for type 2 diabetes?

Ozempic in both forms, Rybelsus, Mounjaro, Victoza, Trulicity and the two insulin combinations. Mounjaro, Victoza and Trulicity are also labeled for children 10 and older. Using a diabetes-only product for weight loss is off-label, a call for a prescriber rather than a table. For more, see semaglutide for type 2 diabetes and Mounjaro for type 2 diabetes.

GLP-1 Pills: The Three Oral Options

Three GLP-1 product lines come as tablets, all taken once a day. Two contain semaglutide; one is a different molecule. Rybelsus and Ozempic tablets share one label and application, so we count them as one line.

• Ozempic tablets (semaglutide), type 2 diabetes. Novo's US successor to Rybelsus, in a new formulation and doses (1.5, 4 and 9 mg), added January 30, 2026. The same label still lists Rybelsus 3, 7 and 14 mg. See is there an Ozempic pill.
• Wegovy tablets (semaglutide), weight management. Approved December 22, 2025, for adults. See is there a Wegovy pill.
• Foundayo (orforglipron), weight management. Approved April 1, 2026, for adults, in six strengths from 0.8 to 17.2 mg. It is a small molecule, not a peptide, and not tirzepatide in pill form. See is there a tirzepatide pill.

Withdrawn, Discontinued and Unclear GLP-1 Drugs

Three different events hide behind "gone". A maker can tell FDA it will stop selling a drug, stock can run out, and FDA can formally withdraw the approval. For Byetta, the maker's notice came in August 2024 and FDA's withdrawal of approval of its original application (NDA 021773) on September 3, 2025. A Byetta label is still posted on DailyMed, and that does not mean the drug is sold.

For Tanzeum and Adlyxin, we found no FDA or manufacturer source giving a discontinuation date. That is a limit of what we could find, not proof that no date exists, so this page states none.

Generic GLP-1 Drugs

Two cautions. Approved is not the same as launched: the liraglutide count is FDA approvals of generic applications, not pharmacy launches or product labels, so label counts elsewhere can differ. And a tentative approval is not a final one. The semaglutide application (Apotex, April 7, 2026) has a marketing status of none in Drugs@FDA.

GLP-1 Drugs That Are Not FDA-Approved

Retatrutide and other investigational agonists

Retatrutide (LY3437943) is Eli Lilly's investigational triple agonist of the GIP, GLP-1 and glucagon receptors. It is not FDA-approved. Lilly has reported Phase 3 results and plans an FDA filing in early 2027. FDA's usual review times would put a decision in late 2027 or 2028 (our estimate, not Lilly's). The details are in is retatrutide FDA approved and the retatrutide hub.

Of the other dual and triple agonists we searched for (survodutide, mazdutide), none appeared in Drugs@FDA or on FDA's 2026 novel drug approvals list when we checked on October 29, 2026.

CagriSema

Novo Nordisk said on December 18, 2025 that it had submitted CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) to FDA for weight management and expected FDA to review it in 2026. It was submitted for FDA review in December 2025 and is not approved as of October 29, 2026.

Compounded and "research" versions

FDA states that compounded drugs are not FDA-approved and that it does not review them for safety, effectiveness or quality before they are marketed. Background: the compounded semaglutide ban and compounded tirzepatide.

What "GLP-3" means

"GLP-3" is an informal term for triple-agonist medications like retatrutide, not an official drug class. See how GLP-1, dual and triple agonists compare.

Warnings Many GLP-1 Labels Share

• Thyroid C-cell tumor boxed warning. Most GLP-1 labels carry it, based on tumors in rodents. Foundayo's version differs: its label says orforglipron is not pharmacologically active in rats or mice, did not produce tumors in rodents, and that human relevance has not been determined.
• Low blood sugar with insulin. The Ozempic, Wegovy, Mounjaro, Zepbound, Foundayo, Victoza, Saxenda, Trulicity and Byetta labels warn that combining with insulin or an insulin secretagogue raises hypoglycemia risk.
• One GLP-1 at a time. The Wegovy, Zepbound, Foundayo, Saxenda, Soliqua and Xultophy labels say use with another GLP-1 receptor agonist is not recommended.

This is not a full safety list, and the labels do not rank one drug as safer than another. Common effects are covered in semaglutide side effects and tirzepatide side effects.

Using This List With Your Prescriber

• Bring the exact brand name and strength. Ozempic and Wegovy share an ingredient but not doses or indications.
• Ask before combining any two products on this page, including a GLP-1 with insulin.
• This list shows what each label covers. Whether a drug fits you, and which one, is your prescriber's call. For how the two biggest molecules differ, see tirzepatide vs semaglutide.

GLP-1 Drugs: Frequently Asked Questions